Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension.

1. Lee S. The value of DNA analysis for antigens of the Kell and Kx blood group systems. Transfusion 2007;47:32S-39S. 2. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43. 3. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002;42:684-90. 4. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617-21. 5. Murphy MT, Fraser RH, Goddard JP. Development of a PCRbased diagnostic assay for the determination of KEL genotype in donor blood samples. Transfus Med 1996;6:133-7. 6. Lee S, Wu X, Son S, Naime D, Reid M, Okubo Y, et al. Point mutations characterize KEL10, the KEL3, KEL4, and KEL21 alleles, and the KEL17 and KEL11 alleles. Transfusion 1996;36:490-4. 7. Lee S, Wu X, Reid M, Redman C. Molecular basis of the K:6,7 [Js(a+b-)] phenotype in the Kell blood group system. Transfusion 1995;35:822-5. 8. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990; 76:1431-7. 9. Schonewille H, van de Watering LMG, Loomans DSE, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 2006;46:250-6. 10. Moreira Jr G, Bordin JO, Kuroda A, Kerbauy J. Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil. Am J Hematol 1996; 52:197-200. 11. Murao M, Viana MB. Risk factors for alloimmunization by patients with sickle cell disease. Braz J Med Biol Res 2005; 38:675-82.